Compare CNVS & BYSI Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | CNVS | BYSI |
|---|---|---|
| Founded | 2000 | 2010 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Consumer Electronics/Video Chains | Biotechnology: Pharmaceutical Preparations |
| Sector | Consumer Discretionary | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 54.7M | 58.4M |
| IPO Year | 2016 | 2016 |
| Metric | CNVS | BYSI |
|---|---|---|
| Price | $2.48 | $1.66 |
| Analyst Decision | Buy | |
| Analyst Count | 1 | 0 |
| Target Price | ★ $9.00 | N/A |
| AVG Volume (30 Days) | ★ 132.3K | 15.1K |
| Earning Date | 02-17-2026 | 05-13-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ 108.99 | N/A |
| EPS | N/A | ★ N/A |
| Revenue | ★ $78,181,000.00 | N/A |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | $84.42 | N/A |
| P/E Ratio | N/A | ★ N/A |
| Revenue Growth | ★ 59.13 | N/A |
| 52 Week Low | $1.77 | $1.18 |
| 52 Week High | $7.39 | $3.44 |
| Indicator | CNVS | BYSI |
|---|---|---|
| Relative Strength Index (RSI) | 46.76 | 60.28 |
| Support Level | $2.31 | $1.46 |
| Resistance Level | $2.67 | $1.75 |
| Average True Range (ATR) | 0.11 | 0.18 |
| MACD | -0.01 | 0.03 |
| Stochastic Oscillator | 21.21 | 100.00 |
Cineverse Corp is a main streaming technology and entertainment company. Its core business operates as a portfolio of owned and operated streaming channels with enthusiast fan bases; a large-scale aggregator and full-service distributor of feature films and television programs; and a proprietary technology software-as-a-service platform for over-the-top (OTT) app development and content distribution through subscription video-on-demand (SVOD), dedicated ad-supported (AVOD), ad-supported streaming linear (FAST) channels, social video streaming services, and audio podcasts. It generates revenue from streaming and digital, Base distribution, Podcast and other, and Other non-recurring.
BeyondSpring Inc is engaged in clinical-stage biopharmaceutical activities focused on the development of cancer therapies. It is also focused on including immuno-oncology agents. It operates in Plinabulin pipeline segment. Its first asset, Plinabulin is a novel brain-penetrant microtubule modulator with dendritic cell maturation and vasculature modulation mechanism, which has the potential to help mitigate acquired resistance from prior immune checkpoint inhibitors (ICI) treatment in cancer patients. It is a Selective Immunomodulating Microtubule-Binding Agent (SIMBA), which may provide multiple therapeutic opportunities.